Author

C. Dirven

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Bolleboom· 1 shared B. B. Oude Munnink· 1 shared B. E. Verstrepen· 1 shared C. Payan· 1 shared C. Verheul· 1 shared C. W. E. Embregts· 1 shared D. van Riel· 1 shared E. Bot· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Bolleboom

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dissecting MPXV neurotropism and host antiviral signaling using human stem cell-based models

L. Bauer, S. Giussani, N. Palazzi, E. Bot, E. Colombo, F. Zare, F. Pinci, L. Leijten, K. Lanko, F. F. W. Benavides, H. Smeenk, C. W. E. Embregts, J. K. H. Spoor, C. Dirven, Z. Gao, , O. Harschnitz

This study investigates MPXV neurotropism and antiviral signaling in CNS cells using human stem cell-derived models, finding that glial cells are more susceptible and exhibit reduced type I IFN responses.

bioRxiv · Aug 25, 2023 · PreprintMicrobiology

Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell cultures

C. Verheul, I. Ntafoulis, T. Kers, Y. Hoogstrate, P. Mastroberardino, S. Barnhoorn, C. Payan, R. Tching Chi Yen, E. Struys, S. Koolen, C. Dirven, S. Leenstra, P. French, M. Lamfers

The paper establishes twelve patient-derived IDH1 mutant glioma cell cultures, confirms their similarity to parental tumors, and identifies nine FDA-approved drugs with activity against IDH-mutant gliomas.

bioRxiv · Apr 9, 2021 · PreprintCancer Biology